Drug profile · INN
brexucabtagene autoleucel
TECARTUS
brexucabtagene autoleucel (TECARTUS) is a b-lymphocyte antigen cd19 binding agent.
Drug details — brexucabtagene autoleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
brexucabtagene autoleucel (TECARTUS) is a b-lymphocyte antigen cd19 binding agent.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights
Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brexucabtagene autoleucel?
brexucabtagene autoleucel (TECARTUS) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for brexucabtagene autoleucel?
TECARTUS is a marketed brand name for brexucabtagene autoleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.